Malarone Junior

Atovaquone/Proguanil, the active ingredient in Malarone Junior, is an antimalarial presented as a 62.5 mg/25 mg chewable tablet for oral use. It prevents malaria infection and treats acute uncomplicated malaria in children. GNH USA supplies Malarone Junior as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Malarone Junior is used within the antimalarial drug class to prevent and treat malaria infections. - Prevention of malaria infection: provides prophylaxis for travelers and residents in endemic areas. - Treatment of acute uncomplicated malaria: clears Plasmodium falciparum, vivax, malariae, and ovale infections in pediatric patients. - Post‑exposure therapy: used after a known bite to reduce risk of disease development.

Malarone Junior may cause a range of adverse reactions.

Common Side Effects: - Abdominal pain: mild to moderate discomfort in the stomach area. - Nausea: feeling of queasiness that may precede vomiting. - Vomiting: expulsion of stomach contents. - Headache: mild to moderate head pain. - Loss of appetite: reduced desire to eat. - Diarrhoea: loose, frequent stools.

Serious or Rare Side Effects: - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic enzyme elevation: increased liver function tests indicating liver stress. - Haematological abnormalities: anemia, neutropenia, or thrombocytopenia. - Hypersensitivity reactions: including rash, fever, or anaphylaxis. - Hemolysis in G6PD deficiency: breakdown of red blood cells in susceptible individuals.

Before prescribing Malarone Junior, consider the following safety measures. - Pregnancy: Category B – use only if clearly needed after risk‑benefit assessment. - Breastfeeding: caution advised; monitor infant for adverse effects. - Renal or hepatic impairment: dose adjustment may be required; monitor function. - G6PD deficiency: avoid use due to risk of hemolysis. - Age restrictions: indicated for children as per approved labeling; verify age‑appropriate dosing. - Concomitant medications: review for potential interactions that may affect efficacy. - Store at room temperature: keep in the original pack, protect from moisture and heat.

Malarone Junior can interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid):\n- Rifampin: reduces atovaquone plasma levels, compromising efficacy. - Antacids containing aluminium or magnesium: decrease absorption of atovaquone. - HIV protease inhibitors (e.g., ritonavir): increase atovaquone concentrations, raising toxicity risk.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect; monitor INR. - Other antimalarials: additive toxicity; assess clinical need. - CYP450 inducers or inhibitors: may alter proguanil metabolism; adjust monitoring accordingly.